Public-registry site landscape for NCT04686175, a Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency study sponsored by Inozyme Pharma. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04686175 (registry record) |
| Sponsor | Inozyme Pharma |
| Condition(s) | Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rickets; Generalized Arterial Calcification of Infancy |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 7 |
| Site countries | United States, Canada, France, Germany, United Kingdom |
Eichor generates a preliminary site-risk snapshot for NCT04686175 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →